Ocular hypotensive effect and safety of travoprost 0.004%/timolol maleate 0.5% fixed combination after change of treatment regimen from &szlig;-blockers and prostaglandin analogs

QR Code

Ocular hypotensive effect and safety of travoprost 0.004%/timolol maleate 0.5% fixed combination after change of treatment regimen from &szlig;-blockers and prostaglandin analogs

Kenji Inoue1, Akira Setogawa1, Risako Higa1, Ryo Moriyama1, Masato Wakakura1, Goji Tomita21Inouye Eye Hospital, Chiyoda-ku, Tokyo, Japan; 22nd Department of Ophthalmology, Toho University School of Medicine, Tokyo, JapanIntroduction: Travoprost 0.004%/timolol maleate 0.5% fixed combination eye drops...

Description complète

Enregistré dans:

Détails bibliographiques
Auteurs principaux:	Inoue K, Setogawa A, Higa R, Moriyama R, Wakakura M, Tomita G
Format:	article
Langue:	EN
Publié:	Dove Medical Press 2012
Sujets:	Ophthalmology RE1-994
Accès en ligne:	https://doaj.org/article/e79031c01f814f9c9867b40e2370e08c
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires

Efficacy and safety of travoprost 0.004%/timolol 0.5% fixed combination as transition therapy in patients previously on prostaglandin analog monotherapy
par: Costa VP, et autres
Publié: (2012)

Efficacy of the travoprost/timolol fixed combination versus the concomitant use of travoprost 0.004% and timolol 0.1% gel formulation
par: Kozobolis V, et autres
Publié: (2018)

Efficacy and safety of fixed-combination travoprost 0.004%/timolol 0.5% in patients transitioning from bimatoprost 0.03%/timolol 0.5% combination therapy
par: Schnober D, et autres
Publié: (2015)

A study of the safety and efficacy of travoprost 0.004%/timolol 0.5% ophthalmic solution compared to latanoprost 0.005% and timolol 0.5% dosed concomitantly in patients with open-angle glaucoma or ocular hypertension
par: Douglas J Rhee, et autres
Publié: (2008)

First experience with BAK-free travoprost 0.004% in topical glaucoma medication
par: Gado AS, et autres
Publié: (2011)

Sustained intraocular pressure reduction throughout the day with travoprost ophthalmic solution 0.004%
par: Dubiner HB, et autres
Publié: (2012)

Assessment of ocular hypotensive effect and safety 12 months after changing from an unfixed combination to a latanoprost 0.005% + timolol maleate 0.5% fixed combination
par: Inoue K, et autres
Publié: (2012)

Efficacy and safety of a switch to latanoprost 0.005% + timolol maleate 0.5% fixed combination eyedrops from latanoprost 0.005% monotherapy
par: Inoue K, et autres
Publié: (2012)

Patient adherence and persistence with topical ocular hypotensive therapy in real-world practice: a comparison of bimatoprost 0.01% and travoprost Z 0.004% ophthalmic solutions
par: Campbell JH, et autres
Publié: (2014)

A randomized crossover study comparing tafluprost 0.005% with travoprost 0.004% in patients with normal-tension glaucoma
par: Mizoguchi T, et autres
Publié: (2012)

Efficacy, safety, and tolerability of travoprost 0.004% BAK-free versus prior treatment with latanoprost 0.005% in Japanese patients
par: Michael J Miyashiro, et autres
Publié: (2010)

Safety and efficacy of switching from dorzolamide 1.0%/timolol maleate 0.5% eye drops to brinzolamide 1.0%/timolol maleate 0.5% eye drops
par: Inoue K, et autres
Publié: (2015)

A comfort comparison of travoprost BAK-free 0.004% versus latanoprost 0.005% in patients with primary open-angle glaucoma or ocular hypertension
par: David A Godfrey, et autres
Publié: (2009)

Efficacy and safety of switching to latanoprost 0.005%–timolol maleate 0.5% fixed-combination eyedrops from an unfixed combination for 36 months
par: Inoue K, et autres
Publié: (2014)

Fixed combination of travoprost and timolol maleate reduces intraocular pressure in Japanese patients with primary open-angle glaucoma or ocular hypertension: analysis by prostaglandin analogue
par: Nakano T, et autres
Publié: (2016)

Randomized trial comparing three fixed combinations of prostaglandins/prostamide with timolol maleate
par: Jaime Pablo Kelly Rigollet, et autres
Publié: (2011)

Intraocular pressure reduction using a fixed combination of timolol maleate 0.5% and brimonidine tartrate 0.2% administered three times daily
par: Moisseiev E, et autres
Publié: (2013)

Efficiency, safety, and patient preference of switching from dorzolamide 1%/timolol 0.5% to brinzolamide 1%/timolol 0.5% while maintaining the prostaglandin F2α analog
par: Shimizu Y, et autres
Publié: (2015)

Safety, tolerability, and efficacy of fixed combination therapy with dorzolamide hydrochloride 2% and timolol maleate 0.5% in glaucoma and ocular hypertension
par: Nicholas P Bell, et autres
Publié: (2010)

Intraocular pressure reduction of fixed combination timolol maleate 0.5% and dorzolamide 2% (Cosopt) administered three times a day
par: Moisseiev E,&nbsp;Lazar M, et autres
Publié: (2012)

Safety and efficacy of changing to the travoprost/timolol maleate fixed combination (DuoTrav) from prior mono- or adjunctive therapy
par: Norbert Pfeiffer, et autres
Publié: (2010)

Addition of a fixed combination of brinzolamide 1%/timolol 0.5% to prostaglandin monotherapy in patients with glaucoma or ocular hypertension
par: Lorenz K, et autres
Publié: (2011)

Efficacy Evaluation of 755-nm Long-Pulse Alexandrite Laser Combined with 0.5% Timolol Maleate Eye Drops in the Treatment of Thicker Infantile Hemangioma
par: Wu J, et autres
Publié: (2021)

Comparison of the latanoprost 0.005%/timolol 0.5% + brinzolamide 1% versus dorzolamide 1%/timolol 0.5% + latanoprost 0.005%: a 12-week, randomized open-label trial
par: Kanamoto T, et autres
Publié: (2012)

Comparison of timolol 0.5% + brimonidine 0.2% + dorzolamide 2% versus timolol 0.5% + brimonidine 0.2% in a Mexican population with primary open-angle glaucoma or ocular hypertension
par: Baiza-Dur&aacute;n LM, et autres
Publié: (2012)

Managing refractory glaucoma with a fixed combination of bimatoprost (0.03%) and timolol (0.5%)
par: Moataz E Gheith, et autres
Publié: (2008)

Additive intraocular pressure-lowering effect of dorzolamide 1%/timolol 0.5% fixed combination on prostaglandin monotherapy in patients with normal tension glaucoma
par: Mizoguchi T, et autres
Publié: (2011)

Fixed combination of topical brimonidine 0.2% and timolol 0.5% for glaucoma and uncontrolled intraocular pressure
par: Anne J Lee, et autres
Publié: (2008)

Preservative-free bimatoprost 0.03%/timolol 0.5% fixed combination in patients with glaucoma in clinical practice
par: Pfennigsdorf S, et autres
Publié: (2016)

Ocular hypotensive effect, preservation of visual fields, and safety of adding dorzolamide to prostaglandin therapy for twelve months
par: Kenji Inoue, et autres
Publié: (2011)

The impact of timolol maleate on the ocular tolerability of fixed-combination glaucoma therapies
par: Radcliffe NM
Publié: (2014)

Efficacy and safety of travoprost/timolol vs dorzolamide/timolol in patients with open-angle glaucoma or ocular hypertension
par: Miguel A Teus, et autres
Publié: (2009)

Administration of the fixed combination of latanoprost 0.005% and timolol 0.5% in glaucoma patients with an intraocular pressure over 30 mmHg
par: Yelda Buyru &Ouml;zkurt, et autres
Publié: (2009)

Treatment persistence and cost-effectiveness of latanoprost/latanoprost&ndash;timolol, bimatoprost/bimatoprost&ndash;timolol, and travoprost/travoprost&ndash;timolol in glaucoma: an analysis based on the United Kingdom general practitioner research database
par: Antoine Lafuma, et autres
Publié: (2011)

Safety and efficacy of fixed-combination travoprost/timolol in patients with open-angle glaucoma or ocular hypertension not controlled with timolol monotherapy
par: Jordão MLS, et autres
Publié: (2014)

Effect of 3 years of treatment with a dorzolamide/timolol (1%/0.5%) combination on intraocular pressure
par: Takeda S, et autres
Publié: (2014)

Preservative toxicity in glaucoma medication: clinical evaluation of benzalkonium chloride-free 0.5% timolol eye drops
par: Rosin LM, et autres
Publié: (2013)

Preservative-free fixed combination of tafluprost 0.0015% and timolol 0.5% in patients with open-angle glaucoma and ocular hypertension: results of an open-label observational study
par: Pillunat LE, et autres
Publié: (2017)

Nonselective &szlig;-blocker propranolol for orbital and periorbital hemangiomas in infants: a new first-line of treatment?
par: El-Essawy R, et autres
Publié: (2011)

Maximum Medical Therapy: Brinzolamide/Brimonidine And Travoprost/Timolol Fixed-Dose Combinations In Glaucoma And Ocular Hypertension
par: Lerner SF, et autres
Publié: (2019)